Re: FDA officially yanks Avastin for breast cancer
At the end of the day, subsets must be identified so treatment can be tailored to the individual. Unfortunately, the baby gets thrown out with the bathwater if a drug only benefits a few, unless of course, as Genentech must now attempt to do, the drug company can identify the subset the drug benefits. Of course, we as members of the Her2 pos subset well know defining who will benefit can be lifesaving.
__________________
Smile On!
Laurel
Dx'd w/multifocal DCIS/IDS 3/08
7mm invasive component
Partial mast. 5/08
Stage 1b, ER 80%, PR 90%, HER-2 6.9 on FISH
0/5 nodes
4 AC, 4 TH finished 9/08
Herceptin every 3 weeks. Finished 7/09
Tamoxifen 10/08. Switched to Femara 8/09
Bilat SPM w/reconstruction 10/08
Clinical Trial w/Clondronate 12/08
Stopped Clondronate--too hard on my gizzard!
Switched back to Tamoxifen due to tendon pain from Femara
15 Years NED
I think I just might hang around awhile....
|